INOTREM
9.1.2023 09:01:51 CET | Business Wire | Press release
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New TOURISE and LIONS Advisory Study Reveals How Creativity Creates a Commercial Advantage for Destination Growth21.10.2026 16:27:00 CEST | Press release
50% of travelers cannot remember the last advertisement they saw for a tourism company or destination, with a further 7% unsureTourism faces an $11 billion marketing investment gap: restoring the category’s share of voice to 3% would require global travel and transport ad spend to reach $43.4 billion by 202763% of Large Language Model (LLM) visibility is driven by long-term brand equity, compared with 22% from current marketing activity and 11% from citation volume TOURISE, the world’s premier platform for shaping the future of global tourism, today released IDEAS That Travel, a new report developed in collaboration with LIONS Advisory. The study finds that while travel demand is rising, tourism brands are competing for attention in a more fragmented, socially driven and AI-mediated environment, where visibility alone is no longer enough to secure preference and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026102116
DEWA International Signs 4 MoUs With Global Partners During WETEX 202621.10.2026 16:12:00 CEST | Press release
DEWA International signed four memorandums of understanding (MoUs) with leading global entities during the Water, Energy, Technology and Environment Exhibition (WETEX 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021351329/en/ DEWA International signs 4 MoUs with global partners during WETEX 2026 (Photo: AETOSWire) HE Saeed Mohammed Al Tayer, MD&CEO of Dubai Electricity and Water Authority (DEWA) and Chairman of DEWA International, said: “We are committed to building strategic partnerships with leading international institutions that possess extensive expertise in developing and implementing energy, water and infrastructure projects, while exploring future collaboration opportunities across key sectors. Through these MoUs, we aim to exchange knowledge and expertise and leverage best practices and advanced technologies. These efforts will help accelerate the transition to clean energy, enhance the resilience and ef
Picsart Launches Marketing Studio to Help Businesses Create, Test and Run Google Ads21.10.2026 16:03:00 CEST | Press release
Key Takeaways: Picsart’s new Marketing Studio brings content creation, advertising strategy, creative testing and paid distribution into one guided space. Businesses can test concepts and videos using Zappi’s consumer insights and predictive technology, then create and launch Google Ads campaigns directly within Picsart. Built primarily for small-business owners, solopreneurs and performance marketeers, Marketing Studio connects creative work with advertising performance, helping businesses use campaign results to guide what they make next. Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today launched Marketing Studio, bringing content creation, advertising strategy, creative testing and paid distribution into one connected experience. Available now, Marketing Studio combines market insights from Zappi with a Google Ads integration that lets businesses create and launch campaigns directly with
Interactive Brokers Introduces Autonomous Trading21.10.2026 16:00:00 CEST | Press release
Eligible clients can authorize connected AI to monitor 75,000+ listed stocks, options and ETFs worldwide and submit supported trades on their behalf based on criteria they define Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced IBKR Autonomous Trading, a new capability that allows eligible clients to authorize connected AI platforms to identify trading opportunities across more than 75,000 listed stocks, options and ETFs worldwide and submit supported orders within a dedicated AI Partition. Clients can create and fund their AI Partition by transferring funds from their main IBKR account, without opening a new account or making an external deposit. The AI operates based on client-defined instructions, subject to account restrictions and safeguards designed to help manage risk. Through natural language, clients can access Interactive Brokers' extensive trading capabilities and define how they want the AI to trade on their behalf. “For decades, Interactive B
DDN and Nebul Accelerate Sovereign AI Inference with DDN Infinia21.10.2026 16:00:00 CEST | Press release
DDN Infinia helps Nebul reuse model context across its NVIDIA-powered AI cloud, with testing showing nearly 10x faster token responses DDN, the global leader in AI and data intelligence solutions, announced today at GTC Berlin 2026 that European AI cloud provider Nebul is using DDN Infinia to accelerate AI inference for sovereign workloads across its NVIDIA-powered infrastructure. Specifically, DDN Infinia is being used to store and reuse key-value (KV) cache, reducing the GPU work required to serve AI models. In testing, DDN helped Nebul sovereign AI workloads find answers faster at a lower cost: Nearly 10x faster time to first token with DDN Infinia than Nebul’s own cache on CPU and memory. Up to 5x faster token responses than alternative solutions. 2.5x more input tokens per second from the same GPUs. Nearly 60% lower cost per million input tokens, by reloading context instead of recomputing it. Testing covered workloads ranging from short prompts to large-token contexts under concu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom